Kelun pads efficacy profile of Merck-partnered ADC; Europe will have to wait for Boehringer's Hernexeos

Data ReadoutpositiveSacituzumab tirumotecanHernexeosPositive

AI Analysis

Summary

Kelun-Biotech announced positive China data for sacituzumab tirumotecan, its Merck-partnered antibody-drug conjugate, demonstrating efficacy as a first-line treatment. The article also notes European approval delays for Boehringer Ingelheim's Hernexeos.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Antibody-drug conjugate succeeded as first-line treatment in China data

Importance:6/10

Sentiment:

0.60

ADConcologyChinapartnershipclinical data

Related Companies

$MRK

Read the original article

Published by Endpoints News on July 16, 2026 3:18 PM

Read Original